v3.26.1
License and Collaboration Agreements - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 01, 2024
USD ($)
Feb. 29, 2024
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
performance_obligation
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Feb. 07, 2024
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Accounts receivable, net       $ 254,484   $ 254,484   $ 139,444 [1]    
Revenue       243,676 $ 110,565 438,191 $ 227,198      
Deferred revenue, current portion       5,546   5,546   7,190 [1]    
Deferred revenue, net of current portion       10,424   10,424   13,080 [1]    
License and services revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue       5,804 37,440 $ 10,223 117,130      
Bayer                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue, remaining performance obligation, amount                 $ 135,000  
Number of performance obligations | performance_obligation           2        
Accounts receivable, net       17,600   $ 17,600   5,000    
Bayer | Seller Parties                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Regulatory and sales milestone payments eligible to receive $ 150,000                  
Revenue, remaining performance obligation, sales milestone payment $ 450,000                  
Bayer | License and services revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Notice period for termination of agreement 270 days                  
Contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized             75,000      
Contract with customer, liability, revenue recognized       200 400 400 700      
Revenue         2,600   78,600      
Bayer | License and services revenue | Seller Parties                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Contract with customer, liability $ 135,000                  
Revenue, remaining performance obligation, regulatory milestone payment $ 210,000                  
Bayer | License                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue, remaining performance obligation, amount                 130,500  
Bayer | Research and Development Services                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Contract with customer, liability       2,500   2,500   2,900    
Revenue, remaining performance obligation, amount                 $ 4,500  
Deferred revenue, current portion       800   800   800    
Deferred revenue, net of current portion       1,700   1,700   2,100    
Bayer | Cost of license, services, and royalty revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue       17,600   27,900        
Kyowa Kirin Co., Ltd                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Contract with customer, liability       11,200   $ 11,200   14,600    
Notice period for termination of agreement   180 days                
Revenue, remaining performance obligation, amount   $ 100,000                
Number of performance obligations | performance_obligation           2        
Deferred revenue, current portion       3,800   $ 3,800   5,400    
Deferred revenue, net of current portion       7,400   7,400   $ 9,200    
Kyowa Kirin Co., Ltd | QED Therapeutics, Inc                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Contract with customer, liability   100,000                
Regulatory and sales milestone payments eligible to receive   81,400                
Revenue, remaining performance obligation, upfront payment   100,000                
Royalty percentage, maximum                   25.00%
Kyowa Kirin Co., Ltd | License and services revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Contract with customer, liability, revenue recognized       1,400 3,500 3,500 5,800      
Revenue       1,800 4,000 4,000 6,700      
Kyowa Kirin Co., Ltd | License                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue, remaining performance obligation, amount   69,100                
Kyowa Kirin Co., Ltd | Research and Development Services                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue, remaining performance obligation, amount   $ 30,900                
Alexion License Agreements | Eidos                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Contract with customer, liability     $ 25,000              
Alexion License Agreements | License and services revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue       $ 1,800 $ 31,000 $ 3,100 $ 32,000      
Alexion License Agreements | License and services revenue | Eidos                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue, remaining performance obligation, regulatory milestone payment     $ 30,000              
[1] The condensed consolidated balance sheet as of December 31, 2025 is derived from the audited consolidated financial statements as of that date.